Natural killer-dendritic cell cross-talk in cancer immunotherapy

Pawel Kalinski, Robbie B. Mailliard, Adam Giermasz, Herbert J. Zeh, Per Basse, David L. Bartlett, John M. Kirkwood, Michael T. Lotze, Ronald B. Herberman

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback. Myeloid DCs, the cell type specialised in the presentation of antigen and initiation of antigen-specific immune responses, have recently been documented to be involved in supporting innate immunity, promoting the production of cytokines and cytotoxicity of NK cells, and enhancing their tumouricidal activity. Natural interferon-producing cells/plasmacytoid DCs (IPCs/PDCs) play an additional role in NK cell activation. Reciprocally, NK cells, traditionally considered to be major innate effector cells, have also recently been shown to play immunoregulatory 'helper' functions, being able to activate DCs and to enhance their ability to produce pro-inflammatory cytokines, and to stimulate T helper (Th) 1 and cytotoxic T lymphocyte (CTL) responses of tumour-specific CD4+ and CD8 + T cells. Activated NK cells induce the maturation of myeloid DCs into stable type-1 polarised DCs (DC1), characterised by up to a 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. In addition, the ability of NK cells to kill tumour cells may facilitate the generation of tumour-related antigenic material, further accelerating the induction of tumour-specific immunity. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumour-related suppressive factors, and demonstrate a strongly enhanced ability to induce Th1 and CTL responses in human in vitro and mouse in vivo models. Compared with the standard mature DCs that are used in clinical trials at present, human NK cell-induced DC1s act as superior inducers of anticancer CTL responses during in vitro sensitisation. This provides a strong rationale for the combined use of NK cells and DCs in the immunotherapy of patients with cancer and patients with chronic infections that are resistant to standard forms of treatment. Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers.

Original languageEnglish (US)
Pages (from-to)1303-1315
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume5
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Natural Killer Cells
Immunotherapy
Dendritic Cells
T-cells
Tumors
Neoplasms
Cytotoxic T-Lymphocytes
Myeloid Cells
Helper-Inducer T-Lymphocytes
Cytokines
Antigens
Clinical Trials
Immune system
Cytotoxicity
Interferons
Histocompatibility Antigens Class II
Antigen Presentation
Cell- and Tissue-Based Therapy
Innate Immunity
Chemical activation

Keywords

  • Cancer
  • Clinical trials
  • Colorectal cancer
  • CTL
  • Dendritic cells
  • HIV
  • Immunotherapy
  • Melanoma
  • NK cells
  • Th1
  • Vaccines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

Kalinski, P., Mailliard, R. B., Giermasz, A., Zeh, H. J., Basse, P., Bartlett, D. L., ... Herberman, R. B. (2005). Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opinion on Biological Therapy, 5(10), 1303-1315. https://doi.org/10.1517/14712598.5.10.1303

Natural killer-dendritic cell cross-talk in cancer immunotherapy. / Kalinski, Pawel; Mailliard, Robbie B.; Giermasz, Adam; Zeh, Herbert J.; Basse, Per; Bartlett, David L.; Kirkwood, John M.; Lotze, Michael T.; Herberman, Ronald B.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 10, 10.2005, p. 1303-1315.

Research output: Contribution to journalReview article

Kalinski, P, Mailliard, RB, Giermasz, A, Zeh, HJ, Basse, P, Bartlett, DL, Kirkwood, JM, Lotze, MT & Herberman, RB 2005, 'Natural killer-dendritic cell cross-talk in cancer immunotherapy', Expert Opinion on Biological Therapy, vol. 5, no. 10, pp. 1303-1315. https://doi.org/10.1517/14712598.5.10.1303
Kalinski, Pawel ; Mailliard, Robbie B. ; Giermasz, Adam ; Zeh, Herbert J. ; Basse, Per ; Bartlett, David L. ; Kirkwood, John M. ; Lotze, Michael T. ; Herberman, Ronald B. / Natural killer-dendritic cell cross-talk in cancer immunotherapy. In: Expert Opinion on Biological Therapy. 2005 ; Vol. 5, No. 10. pp. 1303-1315.
@article{7acdddba1cf84ea69196fd6f8e8f07d5,
title = "Natural killer-dendritic cell cross-talk in cancer immunotherapy",
abstract = "Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback. Myeloid DCs, the cell type specialised in the presentation of antigen and initiation of antigen-specific immune responses, have recently been documented to be involved in supporting innate immunity, promoting the production of cytokines and cytotoxicity of NK cells, and enhancing their tumouricidal activity. Natural interferon-producing cells/plasmacytoid DCs (IPCs/PDCs) play an additional role in NK cell activation. Reciprocally, NK cells, traditionally considered to be major innate effector cells, have also recently been shown to play immunoregulatory 'helper' functions, being able to activate DCs and to enhance their ability to produce pro-inflammatory cytokines, and to stimulate T helper (Th) 1 and cytotoxic T lymphocyte (CTL) responses of tumour-specific CD4+ and CD8 + T cells. Activated NK cells induce the maturation of myeloid DCs into stable type-1 polarised DCs (DC1), characterised by up to a 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. In addition, the ability of NK cells to kill tumour cells may facilitate the generation of tumour-related antigenic material, further accelerating the induction of tumour-specific immunity. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumour-related suppressive factors, and demonstrate a strongly enhanced ability to induce Th1 and CTL responses in human in vitro and mouse in vivo models. Compared with the standard mature DCs that are used in clinical trials at present, human NK cell-induced DC1s act as superior inducers of anticancer CTL responses during in vitro sensitisation. This provides a strong rationale for the combined use of NK cells and DCs in the immunotherapy of patients with cancer and patients with chronic infections that are resistant to standard forms of treatment. Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers.",
keywords = "Cancer, Clinical trials, Colorectal cancer, CTL, Dendritic cells, HIV, Immunotherapy, Melanoma, NK cells, Th1, Vaccines",
author = "Pawel Kalinski and Mailliard, {Robbie B.} and Adam Giermasz and Zeh, {Herbert J.} and Per Basse and Bartlett, {David L.} and Kirkwood, {John M.} and Lotze, {Michael T.} and Herberman, {Ronald B.}",
year = "2005",
month = "10",
doi = "10.1517/14712598.5.10.1303",
language = "English (US)",
volume = "5",
pages = "1303--1315",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Natural killer-dendritic cell cross-talk in cancer immunotherapy

AU - Kalinski, Pawel

AU - Mailliard, Robbie B.

AU - Giermasz, Adam

AU - Zeh, Herbert J.

AU - Basse, Per

AU - Bartlett, David L.

AU - Kirkwood, John M.

AU - Lotze, Michael T.

AU - Herberman, Ronald B.

PY - 2005/10

Y1 - 2005/10

N2 - Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback. Myeloid DCs, the cell type specialised in the presentation of antigen and initiation of antigen-specific immune responses, have recently been documented to be involved in supporting innate immunity, promoting the production of cytokines and cytotoxicity of NK cells, and enhancing their tumouricidal activity. Natural interferon-producing cells/plasmacytoid DCs (IPCs/PDCs) play an additional role in NK cell activation. Reciprocally, NK cells, traditionally considered to be major innate effector cells, have also recently been shown to play immunoregulatory 'helper' functions, being able to activate DCs and to enhance their ability to produce pro-inflammatory cytokines, and to stimulate T helper (Th) 1 and cytotoxic T lymphocyte (CTL) responses of tumour-specific CD4+ and CD8 + T cells. Activated NK cells induce the maturation of myeloid DCs into stable type-1 polarised DCs (DC1), characterised by up to a 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. In addition, the ability of NK cells to kill tumour cells may facilitate the generation of tumour-related antigenic material, further accelerating the induction of tumour-specific immunity. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumour-related suppressive factors, and demonstrate a strongly enhanced ability to induce Th1 and CTL responses in human in vitro and mouse in vivo models. Compared with the standard mature DCs that are used in clinical trials at present, human NK cell-induced DC1s act as superior inducers of anticancer CTL responses during in vitro sensitisation. This provides a strong rationale for the combined use of NK cells and DCs in the immunotherapy of patients with cancer and patients with chronic infections that are resistant to standard forms of treatment. Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers.

AB - Natural killer (NK) cells and dendritic cells (DCs), two important components of the immune system, can exchange bidirectional activating signals in a positive feedback. Myeloid DCs, the cell type specialised in the presentation of antigen and initiation of antigen-specific immune responses, have recently been documented to be involved in supporting innate immunity, promoting the production of cytokines and cytotoxicity of NK cells, and enhancing their tumouricidal activity. Natural interferon-producing cells/plasmacytoid DCs (IPCs/PDCs) play an additional role in NK cell activation. Reciprocally, NK cells, traditionally considered to be major innate effector cells, have also recently been shown to play immunoregulatory 'helper' functions, being able to activate DCs and to enhance their ability to produce pro-inflammatory cytokines, and to stimulate T helper (Th) 1 and cytotoxic T lymphocyte (CTL) responses of tumour-specific CD4+ and CD8 + T cells. Activated NK cells induce the maturation of myeloid DCs into stable type-1 polarised DCs (DC1), characterised by up to a 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. In addition, the ability of NK cells to kill tumour cells may facilitate the generation of tumour-related antigenic material, further accelerating the induction of tumour-specific immunity. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumour-related suppressive factors, and demonstrate a strongly enhanced ability to induce Th1 and CTL responses in human in vitro and mouse in vivo models. Compared with the standard mature DCs that are used in clinical trials at present, human NK cell-induced DC1s act as superior inducers of anticancer CTL responses during in vitro sensitisation. This provides a strong rationale for the combined use of NK cells and DCs in the immunotherapy of patients with cancer and patients with chronic infections that are resistant to standard forms of treatment. Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers.

KW - Cancer

KW - Clinical trials

KW - Colorectal cancer

KW - CTL

KW - Dendritic cells

KW - HIV

KW - Immunotherapy

KW - Melanoma

KW - NK cells

KW - Th1

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=27144538614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144538614&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.10.1303

DO - 10.1517/14712598.5.10.1303

M3 - Review article

C2 - 16197336

AN - SCOPUS:27144538614

VL - 5

SP - 1303

EP - 1315

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -